Research Journal of Oncology Open Access

  • Journal h-index: 3
  • Journal CiteScore: 0.09
  • Journal Impact Factor: 0.09
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days


Cancer Science 2019: bromyalgia and Chronic Pain - Andrea J. Wilson -President & Founder, Blue Faery: The Adrienne Wilson Liver Cancer Association, United States

Andrea J. Wilson

According to the European Respiratory Society, patient advocacy organizations serve three roles: support and advise others; make changes happen; and provide the patient’s perspective. Blue Faery is the only nonprofit in the United States specifically devoted to fighting primary liver cancer, specifically Hepatocellular Carcinoma (HCC), the second most common cause of cancer deaths worldwide. Blue Faery’s mission is to prevent, treat and cure primary liver cancer through research, education and advocacy. Blue Faery has five key values that drive the organization: commitment to outstanding service to patients and caregivers; competence with high quality products; cost effectiveness and efficiency; conscientious collaboration; and communication and transparency. These values ensure that the organization always puts its end users — patients and caregivers — above funders. Blue Faery supports and advises patients and caregivers through its educational materials, online community, one-on-one peer support program and website that translates into nine languages specifically targeted at the HCC patient population. As a member of the Deadliest Cancers Coalition (DCC), Blue Faery works with other nonprofits to make changes happen at the federal level. Most recently, the efforts of the DCC resulted in $2 billion increase for the National Institutes of Health (NIH) for FY2019. Blue Faery works with its partners in a number of ways to provide the patient’s perspective. From online surveys to inperson meetings, Blue Faery brings HCC patients, caregivers and survivors together to facilitate discussions about improving outcomes and increasing access to clinical trials. Conclusion & Significance: When patient advocacy groups serve patients and caregivers, they can make a major impact on not only the quality of life for patients and caregivers, but also on the visibility, funding, research and awareness of the disease.